The promise of proteomics: ​
Multiomics, infectious disease research & therapy development​

Systems biology has been responsible for some of the most important discoveries in life sciences research in recent years. This holistic, interdisciplinary approach combines the analysis of multiple datasets from multiomics studies – including various combinations of genomics, transcriptomics, metabolomics, and more – to help elucidate complex interactions within biological systems, find novel associations between biological components, and highlight useful biomarkers of disease and physiology.

At the heart of this approach is proteomics, the large-scale study of the composition, structure, and function of proteins within an organism. Proteins represent an important class of biomolecule due to their essential role in almost every process within the human body, their intimate connection to phenotype and frequent role as the targets of most drugs and therapeutic development programs.

Traditionally, it has been challenging for researchers to analyze and characterize proteomes in a comprehensive way. However, recent advancements in scientific understanding and the development of new technologies have helped accelerate proteomics research, enabling a deeper understanding of the real-time human biology, underlying health and disease and driving the implementation of drug development and precision medicine.

In the resource below, we explore the new era of proteomics-driven research and how this is an integral tool for answering the biggest questions in human biology.

Find out why proteomics experts - including Professor Matthias Uhlén, the Royal Institute of
Technology, Stockholm - are excited for the future of this field,
in this video interview>>

Case study: The COVID-19 pandemic

The addition of proteomics to multiomic studies is providing vital insights into the dynamic biology underlying human health and disease states.

Most recently, this approach has been integral to advancing our understanding of COVID-19, helping researchers further explain the mechanisms of infection, identify novel biomarkers, monitor progression, and predict patient outcomes and treatment responses.

It is still critical that actionable insights into the novel coronavirus are developed as quickly, efficiently, and safely as possible, while mitigating the additional challenges and pressures of a global pandemic. This amplifies the need for robust and comprehensive lab solutions that enable researchers to rapidly study the proteome in a robust and high-throughput manner to highlight potential biomarkers, elucidate the biological pathways involved, and assess immunological response and disease severity.

Explore the resources below to find out more about how COVID-19 experts are using the latest proteomics platforms to understand the immunology of the disease and see how these insights have the potential to transform future infectious disease research.

Proteogenomics for drug discovery

Recent studies have demonstrated that drug development programs are twice as likely to succeed if they include genetic data. However, many therapeutic studies still fail because they are not targeting the right proteins.

As the pharmaceutical industry looks to more human-based discovery of novel drug targets, proteogenomics – the combination of proteomics and genomics – is proving increasingly important to infer disease causality for a given drug target.

Proteogenomics has the potential to support all aspects of the drug discovery and development pipeline, from target discovery to clinical trials, by providing deeper insight into the underlying biology. Plus, protein biomarkers provide a dynamic and powerful way to predict patient responses to therapy, stratify patient populations, and provide further insight into the onset, progression, and overall biology of a disease.

Find more free resources below that share how including proteomics in multiomics studies can accelerate the search for effective drug targets and ultimately revolutionize drug discovery and precision medicine approaches for the future.

Advances in immunotherapy

Immunotherapy harnesses the power of our own immune system to help the body fight disease and has become a foundation for treating many types of cancer in recent years.

One rapidly emerging area of research is the use of predictive biomarkers, especially plasma-based biomarkers, to improve immunotherapy strategies.

Comprehensive proteomic plasma profiling, especially in combination with RNA analysis from within the tumor environment, can help uncover important immune and tumor pathways and interactions, and the identification of predictive biomarkers enable researchers to detect when there are changes in these relationships. Leveraging such biomarkers enables clinicians to monitor patient response or resistance to immunotherapy and ensure their patients get the right treatment at the right time.

Take a look at the resources exploring how plasma proteomics is being used to predict patient response and resistance to immunotherapy and provide biological insights into tumor-immune system interactions.

Innovative proximity extension assay technology

The Olink® Explore platform and Olink® Target 96 and Target 48 panels comprise high-throughput, multiplex immunoassays of proteins using minimal volumes of almost any type of biological sample, without compromising on data quality or assay robustness.

Watch this short animation to find out more about the proximity extension assay (PEA) technology that lies behind Olink’s proteomics platforms.

"Incredibly innovative PEA technology! Amazing results."

"This product used state-of-the-art technology to allow one drop of blood, less than 3 microliters, to provide information on the protein assays being measured. This allows for incredible insight into real-time human biology to help facilitate the development of more effective and targeted therapies. This in turn allows scientists/researchers to create new drugs while simultaneously continuing with clinical research/basic life science research for possible large-scale discoveries that will address the low abundant plasma proteome."

Amber Kincaid, VUMC
Application Area: Biomarker identification

*Certain images and/or photos on this page are the copyrighted property of, its contributors or its licensed partners and are being used with permission under the relevant license. These images and/or photos may not be copied or downloaded without permission from Other images courtesy of Olink®.